The two source records describe separate securities class actions, rather than the same underlying event. Schall, Brown & Schwartz LLP is urging Regeneron Pharmaceuticals investors from the Aug. 1, 2025-May 15, 2026 class period to contact the firm by Sept. 14, 2026, over allegations involving the Phase III Fianlimab-Libtayo Study, flawed statistical assumptions, and a failure to demonstrate clinical differentiation. The firm is also urging Bloom Energy investors who purchased shares from Feb. 27, 2025, through July 8, 2026, to contact it by Sept. 28, 2026, over allegations that Bloom understated its reliance on China-sourced scandium procured through middlemen. Both proposed classes allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5; neither class has been certified, lead-plaintiff appointment is not required to participate in any recovery, and investors are not represented by counsel until certification.